Research
Hormonal
Myostatin inhibition has potential therapeutic applications for Western diseases like COPD, type II diabetes, and obesity, but may have non-traditional side effects.
Myostatin inhibitors are being researched as treatments for serious conditions like COPD and muscular dystrophy. While promising, they are not yet standard care, and researchers are cautious about potential side effects on heart and fat metabolism.
ModerateConditionalMEDIUM confidence
Based on these effects, myostatin inhibition has potential to be widely utilized in many Western diseases such as chronic obstructive pulmonary disease, type II diabetes and obesity. However, if myostatin inhibitors are to successfully translate from bench-top to bedside in the near future, awareness must be raised on these non-traditional effects of myostatin away from skeletal muscle.
Why this rating
Based on animal models and early human trials; human efficacy is not yet conclusively demonstrated.
Source
The central role of myostatin in skeletal muscle and whole body homeostasis
Bradley Elliott et al. · Acta Physiologica · 2012
DOI 10.1111/j.1748-1716.2012.02423.x
narrative_reviewCited 181×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Myostatin acts as a central negative regulator of skeletal muscle mass by inhibiting myoblast proliferation, increasing ubiquitin-proteasomal activity, and downregulating the IGF-Akt pathway.Good
- Resistance training induces an acute increase in myostatin expression followed by a chronic adaptive decrease in basal levels, facilitating hypertrophy.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →